4.6 Review

From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer

Journal

FRONTIERS IN GENETICS
Volume 14, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fgene.2023.1110656

Keywords

CIP2A/p90; cancer; tumor-associated antigen (TAA); signaling pathways; biomarker; prognosis

Ask authors/readers for more resources

Cancerous inhibitor of protein phosphatase 2A (CIP2A), also known as p90, is highly expressed in various tumors and interacts with protein phosphatase 2A (PP2A) and c-Myc. This interaction hinders PP2A from inducing c-Myc S62 and stabilizes c-Myc protein. CIP2A/p90 plays a crucial role in tumorigenesis, including cell proliferation, invasion, migration, and drug resistance, and has potential as a therapeutic target. Furthermore, autoantibodies against CIP2A/p90 in sera may serve as biomarkers for certain types of cancer diagnosis. This review focuses on recent advances and future research implications of CIP2A/p90.
Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can hinder the function of PP2A toward c-Myc S62 induction, thus stabilizing c-Myc protein, which represents a potential role of CIP2A/p90 in tumorigeneses such as cell proliferation, invasion, and migration, as well as cancer drug resistance. The signaling pathways and regulation networks of CIP2A/p90 are complex and not yet fully understood. Many previous studies have also demonstrated that CIP2A/p90 can be used as a potential therapeutic cancer target. In addition, the autoantibody against CIP2A/p90 in sera may be used as a promising biomarker in the diagnosis of certain types of cancer. In this Review, we focus on recent advances relating to CIP2A/p90 and their implications for future research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available